Ornithine decarboxylase antizyme inhibitor 2 (AZIN2) is a signature of secretory phenotype and independent predictor of adverse prognosis in colorectal cancer

• Tuomas Kaprio ,

  Contributed equally to this work with: Tuomas Kaprio, Tiina Rasila

  Roles Formal analysis, Investigation, Writing – original draft

  * E-mail: tuomas.kaprio@helsinki.fi

  Affiliations Department of Surgery, Helsinki University Central Hospital, Helsinki, Finland, Research Programs Unit, Translational Cancer Biology, University of Helsinki, Helsinki, Finland, Department of Surgery, Lahti Central Hospital, Lahti, Finland

  http://orcid.org/0000-0002-0377-9975

  ⨯
• Tiina Rasila ,

  Contributed equally to this work with: Tuomas Kaprio, Tiina Rasila

  Roles Investigation, Methodology, Writing – original draft

  Affiliation Department of Pathology, Haartman Institute, University of Helsinki and HUSLAB, Helsinki, Finland

  ⨯
• Jaana Hagström,

  Roles Investigation, Writing – review & editing

  Affiliations Research Programs Unit, Translational Cancer Biology, University of Helsinki, Helsinki, Finland, Department of Pathology, Haartman Institute, University of Helsinki and HUSLAB, Helsinki, Finland

  ⨯
• Harri Mustonen,

  Roles Methodology, Software, Writing – review & editing

  Affiliation Department of Surgery, Helsinki University Central Hospital, Helsinki, Finland

  ⨯
• Petri Lankila,

  Roles Investigation, Methodology, Writing – review & editing

  Affiliation Department of Pathology, Haartman Institute, University of Helsinki and HUSLAB, Helsinki, Finland

  ⨯
• Caj Haglund,

  Roles Conceptualization, Funding acquisition, Methodology, Resources, Supervision, Writing – review & editing

  Affiliations Department of Surgery, Helsinki University Central Hospital, Helsinki, Finland, Research Programs Unit, Translational Cancer Biology, University of Helsinki, Helsinki, Finland

  ⨯
• Leif C. Andersson

  Roles Conceptualization, Formal analysis, Methodology, Supervision, Writing – review & editing

  Affiliation Department of Pathology, Haartman Institute, University of Helsinki and HUSLAB, Helsinki, Finland

  ⨯